Literature DB >> 11172021

The role of MHC class I glycoproteins in the regulation of induction of cell death in immunocytes by malignant melanoma cells.

D Fishman1, B Irena, S Kellman-Pressman, M Karas, S Segal.   

Abstract

A deranged expression of MHC class I glycoproteins, characteristic of a variety of malignancies, contributes to the ability of cancer to avoid destruction by T cell-mediated immunity. An abrogation of the metastatic capacity of B16 melanoma cells has been achieved by transfecting an MHC class I-encoding vector into class I-deficient B16 melanoma clones [Gorelik, E., Kim, M., Duty, L. & Galili, U. (1993) Clin. Exp. Metastasis 11, 439-452]. We report here that the deranged expression of class I molecules by B16 melanoma cells is more than a mere acquisition of the capacity to escape immune recognition. Namely, cells of the B16 melanoma prompted splenic lymphocytes to commit death after coculture. However, a class I-expressing and nonmetastatic CL8-2 clone was found to be less potent as an inducer of apoptosis than class I-deficient and metastatic BL9 and BL12 clones. Both Thy1.2(+) and Thy1.2(-) splenocytes underwent cell death when exposed to the class I-deficient BL9 clone. A proportion of CD4(+) and CD8(+) cells among splenocytes exposed to the BL9 clone was lower than that observed in a coculture with cells of the CL8-2 clone. Consistently, none of the melanoma clones studied produced a ligand to the FAS receptor (FAS-L). Thus, our results provide evidence that (i) the production of FAS-L may not be the sole mechanism by which malignant cells induce apoptosis in immunocytes, and (ii) absence of MHC class I glycoproteins plays an important role in preventing the elimination of potential effector immunocytes by tumor cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172021      PMCID: PMC29327          DOI: 10.1073/pnas.98.4.1740

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  The Fas counterattack: cancer as a site of immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Immunol Today       Date:  1999-01

2.  Protective effect of NK1.1(+) T cells as well as NK cells against intraperitoneal tumors in mice.

Authors:  T Kawamura; S Seki; K Takeda; J Narita; Y Ebe; M Naito; H Hiraide; T Abo
Journal:  Cell Immunol       Date:  1999-05-01       Impact factor: 4.868

3.  Mouse NKR-P1B, a novel NK1.1 antigen with inhibitory function.

Authors:  J R Carlyle; A Martin; A Mehra; L Attisano; F W Tsui; J C Zúñiga-Pflücker
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

4.  Human melanoma cells do not express Fas (Apo-1/CD95) ligand.

Authors:  D B Chappell; T Z Zaks; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

5.  Technical note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies.

Authors:  D Smith; S Sieg; D Kaplan
Journal:  J Immunol       Date:  1998-05-01       Impact factor: 5.422

Review 6.  NK cell receptors.

Authors:  L L Lanier
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

7.  Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.

Authors:  T Z Zaks; D B Chappell; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

8.  A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.

Authors:  M Giovarelli; P Musiani; G Garotta; R Ebner; E Di Carlo; Y Kim; P Cappello; L Rigamonti; P Bernabei; F Novelli; A Modesti; A Coletti; A K Ferrie; P L Lollini; S Ruben; T Salcedo; G Forni
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

9.  Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.

Authors:  M Hahne; D Rimoldi; M Schröter; P Romero; M Schreier; L E French; P Schneider; T Bornand; A Fontana; D Lienard; J Cerottini; J Tschopp
Journal:  Science       Date:  1996-11-22       Impact factor: 47.728

10.  Depletion of the natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing fas-ligand: a mechanism of immune evasion.

Authors:  A Khar; C Varalakshmi; B V Pardhasaradhi; A Mubarak Ali; A L Kumari
Journal:  Cell Immunol       Date:  1998-11-01       Impact factor: 4.868

View more
  3 in total

1.  A Potent Inhibitor of Phosphoinositide 3-Kinase (PI3K) and Mitogen Activated Protein (MAP) Kinase Signalling, Quercetin (3, 3', 4', 5, 7-Pentahydroxyflavone) Promotes Cell Death in Ultraviolet (UV)-B-Irradiated B16F10 Melanoma Cells.

Authors:  Rather A Rafiq; Afnan Quadri; Lone A Nazir; Kaiser Peerzada; Bashir A Ganai; Sheikh A Tasduq
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

2.  Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity.

Authors:  Aner Ottolenghi; Priyanka Bolel; Rhitajit Sarkar; Yariv Greenshpan; Muhammed Iraqi; Susmita Ghosh; Baisali Bhattacharya; Zoe V Taylor; Kiran Kundu; Olga Radinsky; Roi Gazit; David Stepensky; Ron N Apte; Elena Voronov; Angel Porgador
Journal:  Sci Rep       Date:  2021-04-07       Impact factor: 4.379

3.  Synthesis and anti-melanoma effect of 3-O-prenyl glycyrrhetinic acid against B16F10 cells via induction of endoplasmic reticulum stress-mediated autophagy through ERK/AKT signaling pathway.

Authors:  Lone A Nazir; Naikoo H Shahid; Kumar Amit; Sheikh A Umar; Sharma Rajni; Sandip Bharate; Pyare L Sangwan; Sheikh Abdullah Tasduq
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.